- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04787198
Investigating Composite Biomarkers for Pain Catastrophizing
February 1, 2024 updated by: Laura Petrini, Aalborg University
Pain is a complex, multidimensional, and subjective experience; and although, investigators use a single word "pain", to describe our perception, multiple mechanisms contribute to the generation and maintenance of pain.
To help diagnosing and improving pain management, there is a need for developing tools.
These tools may include measurements of substances, or biomarkers, in the blood; e.g.
small molecules called microRNA and proteins.
In these experiments, the investigators would like to investigate how the psychological response to stress and pain alters the impulses in the brain and the content of microRNA and proteins in the blood.
The future aim is to identify patients in high risk of developing and maintaining chronic pain and to be able to treat chronic pain efficiently.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
44
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Laura Petrini, PhD
- Phone Number: 0045 99409826
- Email: lap@hst.aau.dk
Study Locations
-
-
-
Aalborg, Denmark, 9220
- Recruiting
- Aalborg University
-
Contact:
- Silvia Lo Vecchio
- Phone Number: +4521397785
- Email: slv@hst.aau.dk
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Healthy men and women in the age 18-80 years
- Speak and understand English
Exclusion Criteria:
- Acute and chronic pain
- Pregnancy or breastfeeding
- Drug addiction defined as the use of cannabis, opioids or other drugs
- Present or previous history of neurological, dermatological, immunological, musculoskeletal, cardiac disorder or mental illnesses that may affect the results (e.g. Neuropathy, muscular pain in the upper extremities, etc.)
- Focal and generalized seizure
- Surgery or any other therapy for epilepsy
- Present or previous AEDs (anti-epileptic drugs) administration
- Present or previous use of epileptic devices (<1 year prior the enrolment)
- Lack of ability to cooperate
- Current use of medications that may affect the trial, such as antipsychotics and pain killers as well as systemic or topical steroids and anti-inflammatory drugs.
- Skin diseases
- Consumption of alcohol or painkillers 24 hours before the study days and between these
- Participation in other trials within 1 week of study entry (4 weeks in the case of pharmaceutical trials)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: isotonic saline
|
The site of injections will be determined by palpation of the contracted First Dorsal Interosseus (FDI) muscle.
The skin will be cleaned with alcohol before injection.
A bolus injection of 0.2 mL isotonic saline (9 mg/mL) will be administered to the FDI muscle as control.
|
Experimental: hypertonic saline
|
The site of injections will be determined by palpation of the contracted First Dorsal Interosseus (FDI) muscle.
The skin will be cleaned with alcohol before injection.
A bolus injection of hypertonic saline (7% NaCl) will be administered to the FDI muscle using a 1 mL syringe with a disposable needle (27G), and 30 the volume of the bolus will be 0.2 mL .
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Oscillations of the main electroencephalogram (EEG) frequency
Time Frame: 10 minutes of recording before isotonic/hypertonic injection
|
Electroencephalographic (EEG) recording will be performed placing a 64-electrodes cap over the scalp according to the 10-20 international system.
Oscillations of the main EEG frequency bands (delta, alpha, beta, gamma) from the frontal and parietal lobes will be detected and correlated to the individual pain rate as well as the dimensions of the psychological questionnaires.
|
10 minutes of recording before isotonic/hypertonic injection
|
Oscillations of the main electroencephalogram (EEG) frequency
Time Frame: 10 minutes of recording after isotonic/hypertonic injection
|
Electroencephalographic (EEG) recording will be performed placing a 64-electrodes cap over the scalp according to the 10-20 international system.
Oscillations of the main EEG frequency bands (delta, alpha, beta, gamma) from the frontal and parietal lobes will be detected and correlated to the individual pain rate as well as the dimensions of the psychological questionnaires.
|
10 minutes of recording after isotonic/hypertonic injection
|
Perturbation of the electroencephalogram (EEG) rhythms
Time Frame: 10 minutes of recording before isotonic/hypertonic injection
|
Electroencephalographic (EEG) recording will be performed placing a 64-electrodes cap over the scalp according to the 10-20 international system.
Perturbation of the above-mentioned EEG rhythms will be measured in response to the hypertonic/isotonic saline injection and compared to a resting state baseline recording.
|
10 minutes of recording before isotonic/hypertonic injection
|
Perturbation of the electroencephalogram (EEG) rhythms
Time Frame: 10 minutes of recording after isotonic/hypertonic injection
|
Electroencephalographic (EEG) recording will be performed placing a 64-electrodes cap over the scalp according to the 10-20 international system.
Perturbation of the above-mentioned EEG rhythms will be measured in response to the hypertonic/isotonic saline injection and compared to a resting state baseline recording.
|
10 minutes of recording after isotonic/hypertonic injection
|
Collection of blood samples
Time Frame: time 0 (baseline)
|
Whole blood samples (5 mL per each time point, a total of 20 mL per subject) will be collected into SST™ II Advance Serum Separation Tubes containing anticoagulant EDTA.
|
time 0 (baseline)
|
Collection of blood samples
Time Frame: Time 1 (3 hours)
|
Whole blood samples (5 mL per each time point, a total of 20 mL per subject) will be collected into SST™ II Advance Serum Separation Tubes containing anticoagulant EDTA.
|
Time 1 (3 hours)
|
Collection of blood samples
Time Frame: time 2 (24 hours)
|
Whole blood samples (5 mL per each time point, a total of 20 mL per subject) will be collected into SST™ II Advance Serum Separation Tubes containing anticoagulant EDTA.
|
time 2 (24 hours)
|
Collection of blood samples
Time Frame: time 3 (48 hours)
|
Whole blood samples (5 mL per each time point, a total of 20 mL per subject) will be collected into SST™ II Advance Serum Separation Tubes containing anticoagulant EDTA.
|
time 3 (48 hours)
|
Collection of blood samples
Time Frame: time 4 (72 hours)
|
Whole blood samples (5 mL per each time point, a total of 20 mL per subject) will be collected into SST™ II Advance Serum Separation Tubes containing anticoagulant EDTA.
|
time 4 (72 hours)
|
MicroRNAs (miRNAs) expression analysis
Time Frame: time 0 (baseline)
|
From the blood samples previously collected, miRNA will be isolated for a subsequent miRNA library preparation.
Subsequently, extracted miRNA will be reversely transcribed, and cDNA will be used for total miRNAs sequencing.
|
time 0 (baseline)
|
MicroRNAs (miRNAs) expression analysis
Time Frame: time 1 (3 hours)
|
From the blood samples previously collected, miRNA will be isolated for a subsequent miRNA library preparation.
Subsequently, extracted miRNA will be reversely transcribed, and cDNA will be used for total miRNAs sequencing.
|
time 1 (3 hours)
|
MicroRNAs (miRNAs) expression analysis
Time Frame: time 2 (24 hours)
|
From the blood samples previously collected, miRNA will be isolated for a subsequent miRNA library preparation.
Subsequently, extracted miRNA will be reversely transcribed, and cDNA will be used for total miRNAs sequencing.
|
time 2 (24 hours)
|
MicroRNAs (miRNAs) expression analysis
Time Frame: time 3 (48 hours)
|
From the blood samples previously collected, miRNA will be isolated for a subsequent miRNA library preparation.
Subsequently, extracted miRNA will be reversely transcribed, and cDNA will be used for total miRNAs sequencing.
|
time 3 (48 hours)
|
MicroRNAs (miRNAs) expression analysis
Time Frame: time 4 (72 hours)
|
From the blood samples previously collected, miRNA will be isolated for a subsequent miRNA library preparation.
Subsequently, extracted miRNA will be reversely transcribed, and cDNA will be used for total miRNAs sequencing.
|
time 4 (72 hours)
|
Proteome analysis
Time Frame: time 0 (baseline)
|
From the blood samples previously collected, the protein concentration will be determined.
Protein sequencing will be done using mass spectrometers.
|
time 0 (baseline)
|
Proteome analysis
Time Frame: time 1(3 hours)
|
From the blood samples previously collected, the protein concentration will be determined.
Protein sequencing will be done using mass spectrometers.
|
time 1(3 hours)
|
Proteome analysis
Time Frame: time 2 (24 hours)
|
From the blood samples previously collected, the protein concentration will be determined.
Protein sequencing will be done using mass spectrometers.
|
time 2 (24 hours)
|
Proteome analysis
Time Frame: time 3 (48 hours)
|
From the blood samples previously collected, the protein concentration will be determined.
Protein sequencing will be done using mass spectrometers.
|
time 3 (48 hours)
|
Proteome analysis
Time Frame: time 4 (72 hours)
|
From the blood samples previously collected, the protein concentration will be determined.
Protein sequencing will be done using mass spectrometers.
|
time 4 (72 hours)
|
Metabolome analysis
Time Frame: time 0 (baseline)
|
From the blood samples previously collected.
Metabolites will be investigated and identified by a 4D feature finding using Metaboscape.
|
time 0 (baseline)
|
Metabolome analysis
Time Frame: time 1(3 hours)
|
From the blood samples previously collected.
Metabolites will be investigated and identified by a 4D feature finding using Metaboscape.
|
time 1(3 hours)
|
Metabolome analysis
Time Frame: time 2 (24 hours)
|
From the blood samples previously collected.
Metabolites will be investigated and identified by a 4D feature finding using Metaboscape.
|
time 2 (24 hours)
|
Metabolome analysis
Time Frame: time 3 (48 hours)
|
From the blood samples previously collected.
Metabolites will be investigated and identified by a 4D feature finding using Metaboscape.
|
time 3 (48 hours)
|
Metabolome analysis
Time Frame: time 4 (72 hours)
|
From the blood samples previously collected.
Metabolites will be investigated and identified by a 4D feature finding using Metaboscape.
|
time 4 (72 hours)
|
Plasma cortisol levels measurement
Time Frame: time 0 (baseline)
|
From the blood samples previously collected, plasma levels of cortisol will be evaluated through enzyme-linked immunosorbent assay (ELISA).
|
time 0 (baseline)
|
Plasma cortisol levels measurements
Time Frame: time 1(3 hours)
|
From the blood samples previously collected, plasma levels of cortisol will be evaluated through enzyme-linked immunosorbent assay (ELISA).
|
time 1(3 hours)
|
Plasma cortisol levels measurements
Time Frame: time 2 (24 hours)
|
From the blood samples previously collected, plasma levels of cortisol will be evaluated through enzyme-linked immunosorbent assay (ELISA).
|
time 2 (24 hours)
|
Plasma cortisol levels measurements
Time Frame: time 3 (48 hours)
|
From the blood samples previously collected, plasma levels of cortisol will be evaluated through enzyme-linked immunosorbent assay (ELISA).
|
time 3 (48 hours)
|
Plasma cortisol levels measurements
Time Frame: time 4 (72 hours)
|
From the blood samples previously collected, plasma levels of cortisol will be evaluated through enzyme-linked immunosorbent assay (ELISA).
|
time 4 (72 hours)
|
Plasma Interleukin-6 (IL-6) levels measurements
Time Frame: time 0 (baseline)
|
From the blood samples previously collected, plasma levels of IL-6 will be evaluated through enzyme-linked immunosorbent assay (ELISA).
|
time 0 (baseline)
|
Plasma Interleukin-6 levels measurements
Time Frame: time 1(3 hours)
|
From the blood samples previously collected, plasma levels of IL-6 will be evaluated through enzyme-linked immunosorbent assay (ELISA).
|
time 1(3 hours)
|
Plasma Interleukin-6 levels measurements
Time Frame: time 2 (24 hours)
|
From the blood samples previously collected, plasma levels of IL-6 will be evaluated through enzyme-linked immunosorbent assay (ELISA).
|
time 2 (24 hours)
|
Plasma Interleukin-6 levels measurements
Time Frame: time 3 (48 hours)
|
From the blood samples previously collected, plasma levels of IL-6 will be evaluated through enzyme-linked immunosorbent assay (ELISA).
|
time 3 (48 hours)
|
Plasma Interleukin-6 levels measurements
Time Frame: time 4 (72 hours)
|
From the blood samples previously collected, plasma levels of IL-6 will be evaluated through enzyme-linked immunosorbent assay (ELISA).
|
time 4 (72 hours)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measuring Pain using VAS
Time Frame: 20 minutes
|
The subject will rate the pain intensity continuously for 20 minutes and VAS will start from zero (0), representing no pain, and will end at one hundred (100) representing worst pain imaginable.
|
20 minutes
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain Catastrophizing Scale (PCS) questionnaire
Time Frame: time 0 (baseline)
|
The PCS assesses negative and exaggerated coping concerning anticipated or experienced painful stimuli.
Thirteen items have to be answered on a 5-points Likert-type scale from 0 (non at all) to 4 (all the time).
|
time 0 (baseline)
|
Positive and Negative Affect Schedule (PANAS) questionnaire
Time Frame: time 0 (baseline)
|
The PANAS measures positive affects (PA) dimensions ( "the extent to which a person feels active, enthusiastic, and alert") and negative affects (NA) dimensions (a condition of "general distress and unpleasable engagement").
Twenty words are associated with the subject's current feelings and have to be rated on a 5-points Likert-type scale from 1 (non at all) to 5 (extremely).
|
time 0 (baseline)
|
Reinforcement Sensitivity Theory - Personality Questionnaire (RST-PQ).
Time Frame: time 0 (baseline)
|
The RST-PQ contains the following subscales:
In total, 65 items have to be answered on a 4-points Likert-type scale, from 1 (non at all) to 4 (highly). |
time 0 (baseline)
|
State-Trait Anxiety Inventory - Form Y (STAI-Y)
Time Frame: time 0 (baseline)
|
The STAI-Y questionnaire measures two types of anxiety, the state and the trait anxiety, as well as the severity of the overall anxiety level.
The questionnaire is divided into two sections of 20 items each to be rated on a 4-points Likert-type scale from 1 (non at all) to 4 (very much).
|
time 0 (baseline)
|
Heart rate assessment
Time Frame: time 0 (baseline)
|
An electrocardiogram (ECG) will be recorded with a standard 3-lead montage (one electrode on each wrist and the third on the left ankle)
|
time 0 (baseline)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Laura Petrini, PhD, Aalborg University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 15, 2022
Primary Completion (Estimated)
December 31, 2024
Study Completion (Estimated)
December 31, 2025
Study Registration Dates
First Submitted
February 16, 2021
First Submitted That Met QC Criteria
March 5, 2021
First Posted (Actual)
March 8, 2021
Study Record Updates
Last Update Posted (Actual)
February 2, 2024
Last Update Submitted That Met QC Criteria
February 1, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- N-20200095
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain, Acute
-
Rajavithi HospitalCompletedTotal Abdominal Hysterectomy ,Pain , Acute Postoperative,Gabapentin , CelecoxibThailand
-
Schulthess KlinikNot yet recruiting
-
Seoul National University HospitalNot yet recruiting
-
Chung-Ang University Gwangmyeong HospitalRecruitingPostoperative Pain, AcuteKorea, Republic of
-
TC Erciyes UniversityCompletedPostoperative Pain, AcuteTurkey
-
Northwell HealthRecruitingPain, Postoperative | Postoperative Pain, AcuteUnited States
-
Zagazig UniversityRecruiting
-
Mansoura UniversityRecruitingPostoperative Pain, AcuteEgypt
-
University of California, San DiegoActive, not recruitingPostoperative Pain, AcuteUnited States
-
Umraniye Education and Research HospitalNot yet recruiting
Clinical Trials on hypertonic saline
-
University of North Carolina, Chapel HillNational Heart, Lung, and Blood Institute (NHLBI)RecruitingModerate to Severe AsthmaUnited States
-
Western States Endurance Run Research FoundationUnknownExercise-associated HyponatremiaUnited States
-
Regional Hospital HolstebroCompleted
-
Aalborg UniversityThe Danish Rheumatism AssociationCompleted
-
Cairo UniversityCompletedOptic Nerve Sheath | Hypertonic SalineEgypt
-
Dr. Michael FlavinWithdrawn
-
Nicole HamblettUniversity of Washington; Dartmouth-Hitchcock Medical Center; Cystic Fibrosis...Completed
-
Szpital im. Św. Jadwigi ŚląskiejRecruiting